CN1863560A - 用于促进止血的血纤蛋白原靶向微粒 - Google Patents
用于促进止血的血纤蛋白原靶向微粒 Download PDFInfo
- Publication number
- CN1863560A CN1863560A CNA200480029425XA CN200480029425A CN1863560A CN 1863560 A CN1863560 A CN 1863560A CN A200480029425X A CNA200480029425X A CN A200480029425XA CN 200480029425 A CN200480029425 A CN 200480029425A CN 1863560 A CN1863560 A CN 1863560A
- Authority
- CN
- China
- Prior art keywords
- fibrinogen
- product
- platelet
- peptide
- platelets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0323378.0 | 2003-10-07 | ||
| GBGB0323378.0A GB0323378D0 (en) | 2003-10-07 | 2003-10-07 | Therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1863560A true CN1863560A (zh) | 2006-11-15 |
Family
ID=29415609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200480029425XA Pending CN1863560A (zh) | 2003-10-07 | 2004-10-07 | 用于促进止血的血纤蛋白原靶向微粒 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080064628A1 (enExample) |
| EP (1) | EP1677829B1 (enExample) |
| JP (2) | JP4938454B2 (enExample) |
| CN (1) | CN1863560A (enExample) |
| AU (1) | AU2004280115B2 (enExample) |
| CA (1) | CA2541005C (enExample) |
| GB (1) | GB0323378D0 (enExample) |
| IL (1) | IL174580A0 (enExample) |
| WO (1) | WO2005035002A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687061B (zh) * | 2006-11-27 | 2013-03-27 | 哈莫斯塔蒂斯有限公司 | 生物凝胶 |
| CN107592814A (zh) * | 2015-05-11 | 2018-01-16 | 哈莫斯塔蒂斯有限公司 | 止血组合物 |
| CN110448719A (zh) * | 2019-06-28 | 2019-11-15 | 浙江大学 | 一种促进凝血的丝素-多肽电纺膜及其制备方法 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0516091D0 (en) | 2005-08-04 | 2005-09-14 | Haemostatix Ltd | Therapeutic agent |
| US9114127B2 (en) * | 2007-05-15 | 2015-08-25 | Richard C. K. Yen | Biologic devices for hemostasis |
| KR20100057641A (ko) * | 2007-09-11 | 2010-05-31 | 몬도바이오테크 래보래토리즈 아게 | 인터메딘 ４７ 및 ５３ 펩티드의 치료적 용도 |
| KR20100061487A (ko) * | 2007-09-11 | 2010-06-07 | 몬도바이오테크 래보래토리즈 아게 | 펩티드 ｙｇｌｆ 및 ｋｖｌｐｖｐｑ와의 배합물의 치료적 용도 |
| GB201101740D0 (en) * | 2011-02-01 | 2011-03-16 | Haemostatix Ltd | Therapeutic agents with improved fibrinogen binding |
| GB201201751D0 (en) * | 2012-02-01 | 2012-03-14 | Haemostatix Ltd | Haemostatic wound dressing |
| GB201204868D0 (en) | 2012-03-20 | 2012-05-02 | San Raffaele Centro Fond | Peptides |
| AU2013334180A1 (en) * | 2012-10-25 | 2015-05-14 | The Children's Hospital Of Philadelphia | Affinity peptide-modified particles and targeted drug delivery methods |
| WO2017103914A1 (en) | 2015-12-17 | 2017-06-22 | Regentis Biomaterials Ltd. | Ready for use organic solvent free compositions comprising protein-polymer conjugates and uses thereof |
| WO2020113090A1 (en) | 2018-11-30 | 2020-06-04 | Cellphire, Inc. | Platelets as delivery agents |
| US11767511B2 (en) | 2018-11-30 | 2023-09-26 | Cellphire, Inc. | Platelets as delivery agents |
| CA3138529C (en) | 2019-05-03 | 2025-10-07 | Cellphire Inc | Materials and methods for producing blood products |
| WO2021034719A1 (en) | 2019-08-16 | 2021-02-25 | Cellphire, Inc. | Thrombosomes as an antiplatelet agent reversal agent |
| CA3170134A1 (en) | 2020-02-04 | 2021-08-12 | Cellphire, Inc. | Treatment of von willebrand disease |
| US20220273724A1 (en) | 2021-02-17 | 2022-09-01 | Cellphire Inc. | Freeze-dried platelet derivative compositions for treating antiplatelet induced coagulopathy |
| CN118302431A (zh) * | 2021-10-15 | 2024-07-05 | 北卡罗来纳大学 | 用于纯化生物流体的组合物和方法 |
| WO2024163622A1 (en) * | 2023-01-31 | 2024-08-08 | North Carolina State University | Compositions and methods for purifying biological fluids |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5357042A (en) * | 1984-04-23 | 1994-10-18 | The General Hospital Corporation | Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity |
| US6391343B1 (en) * | 1991-01-15 | 2002-05-21 | Hemosphere, Inc. | Fibrinogen-coated particles for therapeutic use |
| DE4310632A1 (de) | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Lineare Adhäsionsinhibitoren |
| CN1175208A (zh) * | 1994-12-16 | 1998-03-04 | 安达里斯有限公司 | 交联的微粒及其作为治疗载体的用途 |
| EP1028752B1 (en) | 1996-10-21 | 2004-12-15 | Quadrant Drug Delivery Limited | Platelet substitutes and conjugation methods suitable for their preparation |
| GB9724143D0 (en) * | 1997-11-14 | 1998-01-14 | Andaris Ltd | Pharmaceutical conjugate |
| CA2320219A1 (en) | 1998-02-20 | 1999-08-26 | Quadrant Healthcare (Uk) Limited | Products comprising fibrinogen for use in therapy |
| US20040127416A1 (en) | 2002-11-15 | 2004-07-01 | Massia Stephen P. | Therapeutic bioconjugates |
-
2003
- 2003-10-07 GB GBGB0323378.0A patent/GB0323378D0/en not_active Ceased
-
2004
- 2004-10-07 CN CNA200480029425XA patent/CN1863560A/zh active Pending
- 2004-10-07 JP JP2006530592A patent/JP4938454B2/ja not_active Expired - Fee Related
- 2004-10-07 CA CA2541005A patent/CA2541005C/en not_active Expired - Fee Related
- 2004-10-07 WO PCT/GB2004/004235 patent/WO2005035002A1/en not_active Ceased
- 2004-10-07 EP EP04768770.2A patent/EP1677829B1/en not_active Expired - Lifetime
- 2004-10-07 US US10/574,872 patent/US20080064628A1/en not_active Abandoned
- 2004-10-07 AU AU2004280115A patent/AU2004280115B2/en not_active Ceased
-
2006
- 2006-03-27 IL IL174580A patent/IL174580A0/en unknown
-
2011
- 2011-06-28 JP JP2011143587A patent/JP2011184465A/ja not_active Withdrawn
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687061B (zh) * | 2006-11-27 | 2013-03-27 | 哈莫斯塔蒂斯有限公司 | 生物凝胶 |
| US9339584B2 (en) | 2006-11-27 | 2016-05-17 | Haemostatix Limited | Biogel |
| US9913876B2 (en) | 2006-11-27 | 2018-03-13 | Haemostatix Limited | Biogel |
| CN107592814A (zh) * | 2015-05-11 | 2018-01-16 | 哈莫斯塔蒂斯有限公司 | 止血组合物 |
| CN110448719A (zh) * | 2019-06-28 | 2019-11-15 | 浙江大学 | 一种促进凝血的丝素-多肽电纺膜及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004280115A1 (en) | 2005-04-21 |
| EP1677829B1 (en) | 2014-12-24 |
| US20080064628A1 (en) | 2008-03-13 |
| GB0323378D0 (en) | 2003-11-05 |
| EP1677829A1 (en) | 2006-07-12 |
| JP2011184465A (ja) | 2011-09-22 |
| CA2541005A1 (en) | 2005-04-21 |
| AU2004280115B2 (en) | 2011-03-24 |
| IL174580A0 (en) | 2006-08-20 |
| WO2005035002A1 (en) | 2005-04-21 |
| JP2007507480A (ja) | 2007-03-29 |
| CA2541005C (en) | 2012-05-08 |
| JP4938454B2 (ja) | 2012-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1863560A (zh) | 用于促进止血的血纤蛋白原靶向微粒 | |
| JP6865253B2 (ja) | 免疫調節方法及び組成物 | |
| JP7580202B2 (ja) | 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法 | |
| JP2021130721A (ja) | 合成膜−レシーバー複合体 | |
| JP5204490B2 (ja) | 出血の制御及び出血性疾患の治療のための止血剤としての細胞由来微粒子 | |
| JP2007507480A5 (enExample) | ||
| TW201335371A (zh) | Ａｆｏｄ及ａｆｃｃ之方法以及蛋白質之製備及純化方法 | |
| CN106659771B (zh) | 修饰的von Willebrand因子 | |
| JPWO2014208100A1 (ja) | 間葉系細胞を利用した巨核球、血小板及び／又はトロンボポエチンの製造方法 | |
| JPWO2014208100A6 (ja) | 間葉系細胞を利用した巨核球、血小板及び／又はトロンボポエチンの製造方法 | |
| JP2009505964A (ja) | 人工血小板 | |
| FR2940087A1 (fr) | Erythrocytes contenant du facteur viii, preparation et utilisations. | |
| JP2017516752A (ja) | 単離されたドナーｍｈｃ由来ペプチド及びその使用 | |
| TW201828975A (zh) | 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類 | |
| US11141466B2 (en) | Modulation of FVIII immunogenicity by truncated VWF | |
| RU2709738C1 (ru) | Композиции для инъекций на основе коллагена, способные контролировать кровотечение и/или замещать тромбоциты при геморрагических синдромах | |
| US20250295734A1 (en) | Anticoagulant proteins and their use for treating diseases associated with the activation of neutrophils | |
| WO2024019080A1 (ja) | 血管内皮増殖因子を高発現する臍帯由来間葉系細胞の製造方法、および肺疾患治療用医薬組成物 | |
| WO2025037108A2 (en) | Modified thrombopoietin | |
| AU2017268526A1 (en) | Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions | |
| CN1826136A (zh) | 治疗血友病的含Ⅷ因子和IXa因子的组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20061115 |